Trial Profile
Phase 2 study of SAB-301 in patients with Middle-East-respiratory-syndrome-coronavirus
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2024
At a glance
- Drugs MERS monoclonal antibody (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Therapeutic Use
Most Recent Events
- 20 Jun 2024 According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO.
- 14 Sep 2016 New trial record
- 24 Aug 2016 According to SAB Biotherapeutics media release, this trial is conducted by the National Institutes of Health (NIH).
Trial Overview
Purpose
This phase 2 study will investigate the effect of SAB-301 in patients with Middle-East-respiratory-syndrome-coronavirus.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| Middle East respiratory syndrome coronavirus | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
- Age Group adult
Patient Inclusion Criteria
- patients with Middle-East-respiratory-syndrome-coronavirus
Trial Details
Organisations
- Affiliations SAB BIO
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase II
- Location Unknown
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation | Target |
|---|---|---|---|
|
MERS monoclonal antibody Primary Drug
|
Intravenous |
-
|
-
|
SAB-301
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 20 Jun 2024 | Other trial event | According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO. Updated 25 Jul 2024 |
| 14 Sep 2016 | New trial record | New trial record Updated 14 Sep 2016 |
| 24 Aug 2016 | Other trial event | According to SAB Biotherapeutics media release, this trial is conducted by the National Institutes of Health (NIH). Updated 14 Sep 2016 |
References
-
SAB Biotherapeutics. SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment. Media-Rel 2016;.
Media Release -
SAB Biotherapeutics. SAb Biotherapeutics Rebrands as SAB BIO. Media-Rel 2024;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG